Related Experiment Video
Updated: Aug 26, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Research progress in targeted therapies for gastric cancer
Abstract:
Patients with advanced gastric cancer experience rapid disease progression with limited survival, high mortality, and a lack of surgical options. Thus, radiochemotherapy or a combination of chemotherapeutics with targeted therapy is the mainstay of treatment. In comparison to the treatment of other malignant tumors, in gastric cancer, the development of molecularly targeted drugs has been relatively slow. Currently, there are two major classes of molecularly targeted drug regimens that have achieved a certain efficacy in clinical practice: anti-vascular endothelial growth factor (anti-VEGF) therapy and anti-epidermal growth factor receptor (anti-EGFR) therapy. Trastuzumab has been approved as the standard of care for first-line treatment in advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer. Ramucirumab in combination with paclitaxel is the recommended regimen for second-line treatment, and apatinib is recommended as third-line treatment. This review summarizes the current status of targeted therapies in the treatment of gastric cancer and gives a perspective on the future.
Insights
Targeted therapies, including anti-vascular endothelial growth factor (anti-VEGF) and anti-epidermal growth factor receptor (anti-EGFR) treatments, offer new options for advanced gastric cancer. These therapies are crucial given limited surgical choices and the slow development of molecularly targeted drugs.
Area of Science:
- Oncology
- Medical Science
Background:
- Advanced gastric cancer presents significant challenges, including rapid progression, poor survival rates, and limited surgical interventions.
- Radiochemotherapy and combination therapies are primary treatments, but molecularly targeted drug development has lagged compared to other cancers.
Approach:
- This review examines the current landscape of molecularly targeted therapies for gastric cancer.
- Focuses on anti-vascular endothelial growth factor (anti-VEGF) and anti-epidermal growth factor receptor (anti-EGFR) therapies, which have shown clinical efficacy.
Key Points:
- Trastuzumab is a standard first-line treatment for HER2-positive advanced gastric cancer.
- Ramucirumab with paclitaxel is recommended for second-line therapy, and apatinib for third-line treatment.
- Targeted therapies represent a critical advancement in managing advanced gastric cancer.
Conclusions:
- The review summarizes the current status of targeted therapies in gastric cancer treatment.
- Provides insights into future directions and potential advancements in molecularly targeted drug development for gastric cancer.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
